Metabolism - Clinical and Experimental
Volume 52, Issue 9 , Pages 1147-1152 , September 2003

Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action

  • C.Hamish Courtney

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • David R McCance

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • A.Brew Atkinson

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Jonathan Bassett

      Affiliations

    • Montalto Health Clinic, Balynahinch, Co. Down, United Kingdom
    • ,
  • Cieran N Ennis

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Brian Sheridan

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Patrick M Bell

      Affiliations

    • Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom
    • Corresponding Author InformationAddress reprint requests to Patrick M. Bell, MD, East Wing Office, Royal Victoria Hospital, Belfast, UK BT12 6BA

Received 27 September 2002 ,Accepted 22 April 2003.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported by a Royal Victoria Hospital Research Fellowship (to C.H.C.), Royal Victoria Hospital Metabolic Unit Research Fund, and Pfizer UK (to C.H.C. and P.M.B.).

PII: S0026-0495(03)00190-2

doi: 10.1016/S0026-0495(03)00190-2

Metabolism - Clinical and Experimental
Volume 52, Issue 9 , Pages 1147-1152 , September 2003

Article Tools

* Image Usage & Resolution